CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

BACKGROUND: Osimertinib is an oral, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor activating mutation (EGFRm) and the resistance mutation (T790M) that is FDA approved for patients with EGFR mutant lung cancer. The synergism between Osimertinib and rad...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Rauf, Yasmeen, Kotecha, Rupesh, Fadul, Camilo, Evanoff, Wendi, Suh, John, Chao, Samuel, Murphy, Erin, Yu, Jennifer, Angelov, Lilyana, Barnett, Gene, Mohammadi, Alireza, Ahluwalia, Manmeet
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Trials: Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.156
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi